In summary, the elevated serum chemokines CXCL2 and CXCL5, in conjunction with a low level of CCL23, may contribute towards suppressed antitumor immunity and account for lethal prostate cancer in AA men. The gene discussed is CXCL2; the disease is prostate cancer.